Metacrine, Inc.
CRYSTALLINE FORMS OF A FARNESOID X RECEPTOR AGONIST
Last updated:
Abstract:
Described herein is the farnesoid X receptor agonist, trans-N-(3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl)-4-hydroxy-N-((trans-4-(- 4-methoxy-3-methyl phenyl)cyclohexyl)methyl)cyclohexane-carboxamide, including crystalline forms and pharmaceutically acceptable salts, solvates, and formulations thereof.
Status:
Application
Type:
Utility
Filling date:
17 Sep 2019
Issue date:
11 Nov 2021